Trupanion has crossed from cash-consuming pet-insurance growth into self-funded compounding, and the equity still prices that turn as fragile. Subscription adjusted operating income, the profit measure that strips new-pet acquisition spend and stock compensation, now sits at the long-stated fifteen percent target. Operating cash covers enrollment spend, and a regulator-approved dividend from American Pet Insurance Company has moved surplus to the holding company for a new repurchase program. The debate is whether the branded book can keep compounding after the Pets Best underwriting contract ends.
The latest quarter shows the mix shift already in motion. Subscription revenue rose fourteen percent to $277 million while the other-business book kept shrinking on Pets Best runoff, so a larger share of the top line now carries the higher-margin product. Net subscription adds of roughly nineteen thousand pets jumped as web conversion improved and expanded deductible options reached about half of North America. Lifetime value of a new pet rose twenty-five percent even as acquisition cost climbed to $299. The bear case is that veterinary inflation remains in double digits and new hospital visits are down across the industry, so price has to do more work than volume.
Reported earnings look weaker only because the year-ago print included a one-time preferred-stock gain. Trailing free cash flow now exceeds $82 million. Management narrowed full-year adjusted operating income to a band around $180 million and authorized a $100 million repurchase after the New York insurance regulator cleared the American Pet Insurance Company dividend. The question for the next year is whether subscription pet adds and claims discipline replace Pets Best premiums fast enough that the multiple starts to treat Trupanion as a compounding specialty insurer rather than a shrinking underwriting platform.